Syneos Health Experts to Debate CNS Trial Endpoints in Dec. 1 Webinar
Toronto -- Syneos Health experts will lead a free webinar on December 1, 2026, at 11am EST (5pm CET) on how neuroscience sponsors are changing patient identification, endpoint selection and treatment-response assessment across CNS disorders. Xtalks is hosting the session, titled "Neuroscience Development: Are We Measuring What Matters?"
Disease heterogeneity and response variability are pressuring traditional trial design
Alzheimer's disease, Parkinson's disease and psychiatry trials face disease heterogeneity, limited trial accessibility and variable treatment response. These factors are forcing sponsors to reassess how they identify patients, measure treatment effects and make development decisions. Panelists will examine why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change.